SNDX vs. ADMA, ZLAB, RNA, OGN, ACLX, SWTX, RARE, AKRO, ALVO, and IMVT
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include ADMA Biologics (ADMA), Zai Lab (ZLAB), Avidity Biosciences (RNA), Organon & Co. (OGN), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Alvotech (ALVO), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.
Syndax Pharmaceuticals vs.
Syndax Pharmaceuticals (NASDAQ:SNDX) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
Syndax Pharmaceuticals has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Syndax Pharmaceuticals presently has a consensus target price of $36.20, suggesting a potential upside of 169.35%. ADMA Biologics has a consensus target price of $22.50, suggesting a potential upside of 11.28%. Given Syndax Pharmaceuticals' higher probable upside, equities analysts plainly believe Syndax Pharmaceuticals is more favorable than ADMA Biologics.
ADMA Biologics has a net margin of 17.80% compared to Syndax Pharmaceuticals' net margin of 0.00%. ADMA Biologics' return on equity of 53.20% beat Syndax Pharmaceuticals' return on equity.
75.7% of ADMA Biologics shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ADMA Biologics received 23 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 72.13% of users gave ADMA Biologics an outperform vote while only 65.60% of users gave Syndax Pharmaceuticals an outperform vote.
In the previous week, ADMA Biologics had 10 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 18 mentions for ADMA Biologics and 8 mentions for Syndax Pharmaceuticals. ADMA Biologics' average media sentiment score of 1.17 beat Syndax Pharmaceuticals' score of 0.57 indicating that ADMA Biologics is being referred to more favorably in the news media.
ADMA Biologics has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
ADMA Biologics beats Syndax Pharmaceuticals on 14 of the 19 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SNDX) was last updated on 3/25/2025 by MarketBeat.com Staff
